Blogs
Welcome to Unibest's Blogs section! Here, you will find valuable insights and in-depth reports covering various topics related to drugs and diseases. Our blogs aim to provide an enhanced understanding of the clinical significance and breakthroughs your clients can make. Stay updated with the latest trends, technological advancements, and industry analyses as we dive deep into the world of pharmaceuticals, giving you the knowledge and resources you need to stay ahead of the competition.

Ivacaftor

The articles shown below are all about the Ivacaftor, through these related articles, you can get relevant information, notes in use, or latest trends about the Ivacaftor. We hope these news will give you the help you need. And if these Ivacaftor articles can't solve your needs, you can contact us for relevant information.
  • Drug Patent & Exclusivity Expiration Report - Week of Feb 10 2025

    2025-02-10

    This week, there are 6 drugs in the patent and exclusivity list. They are: - Tudorza Pressair by Covis Pharma GMBH, containing active ingredient Aclidinium Bromide - Duaklir Pressair by Covis Pharma GMBH, containing active ingredient Aclidinium Bromide and Formoterol Fumarate - Scenesse by Clinuvel Inc, containing active ingredient Afamelanotide - Hysingla ER by Purdue Pharma LP, containing active ingredient Hydrocodone Bitartrate - Izervay by Astellas Pharma US Inc, containing active ingredient Avacincaptad Pegol Sodium - Symdeko by Vertex Pharmaceuticals Inc, containing active ingredient Ivacaftor and Tezacaftor Read More
  • Drug Patent & Exclusivity Expiration Report - Week of Oct 21 2024

    2024-10-22

    This week, there are 3 drugs in the patent and exclusivity list. They are: - BRISTOL-MYERS SQUIBB CO's ABRAXANE, containing active ingredient PACLITAXEL - VERTEX PHARMACEUTICALS INC's TRIKAFTA (COPACKAGED), containing active ingredient ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR - BAUSCH AND LOMB INC's XIPERE, containing active ingredient TRIAMCINOLONE ACETONIDE Read More